Innate Pharma SA in brief
Innate Pharma SA is a listed company in the Biotechnology industry, based in France. Its last known market value was $230 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $10 M and a net loss of $55 M. It employs about 181 people. Its shares trade under the symbol IPHYF (EURONEXT).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Innate Pharma SA
Even if the Company completes the necessary preclinical and clinical studies, the marketing approval process is expensive, time-consuming and uncertain and may prevent the Company from obtaining approvals for the commercialization of some or all of its product candidates. If the Company is not able to obtain, or if there are delays in obtaining, required regulatory approvals, in particular in the United States or the European Union, the Company will not be able to commercialize its product candidates, and its ability to generate revenue will be materially impaired.
The research and development of pharmaceutical products is governed by complex regulatory requirements. The regulatory agencies that oversee these requirements have the authority to permit the commencement and maintenance of clinical studies or to temporarily halt or terminate a study. They are entitled to request additional clinical data before authorizing the commencement or resumption of a study, which could result in delays or changes to the product development plan. As the Company advances its product candidates, the Company will be required to consult with these regulatory agencies for regulatory approval and comply with all applicable guidelines, rules and regulations. If the Company fails to do so, the Company may be required to delay or discontinue a clinical study of its product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease its ability to generate sufficient product revenue to maintain its business.
From the company's annual report filed with the US SEC: read the report
Innate Pharma SA timeline
- 1999
- 🏁· approximateIncorporated as Innate Pharma
- 2014
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- •Legal Entity Identifier issuedLEI 9695002Y8420ZB8HJE29 registered.
- 2019
- 🔔Initial public offeringFinal prospectus filed with the SEC on 18 October 2019; shares registered for exchange trading on 10 October 2019.
Events of Innate Pharma SA from the GLEIF LEI register and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in France: #187 (Jan 2020) · #240 (Jan 2021) · #223 (Jan 2022) · #247 (Dec 2022) · #240 (Jul 2023) · #230 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -545.9%
- Operating margin
- -599.5%
- Return on equity
- —
- Liabilities / assets
- 134.6%
- Revenue growth
- -53.3%
- R&D / revenue
- 484.2%
- Revenue per employee
- $56 K
- Profit per employee
- $-306 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $10M | -53.3% | $-61M | $-55M | -545.9% |
| Dec 2024 | $22M | -67.3% | $-56M | $-54M | -245.9% |
| Dec 2023 | $67M | +10.0% | $-14M | $-8M | -12.3% |
| Dec 2022 | $61M | +107.5% | $-60M | $-61M | -100.7% |
| Dec 2021 | $29M | -63.3% | $-57M | $-62M | -213.8% |
| Dec 2020 | $80M | -16.8% | $1M | $-73M | -91.7% |
| Dec 2019 | $96M | -13.7% | $2M | $-23M | -24.3% |
| Dec 2018 | $111M | — | $6M | $4M | 3.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-60M | $0M | $-60M | $-0.62 | — |
| Dec 2024 | $-7M | $0M | $-8M | $-0.66 | — |
| Dec 2023 | $-35M | $0M | $-36M | $-0.10 | — |
| Dec 2022 | $-20M | $1M | $-21M | $-0.77 | — |
| Dec 2021 | $-69M | $1M | $-70M | $-0.78 | — |
| Dec 2020 | $-59M | $1M | $-60M | $-0.92 | — |
| Dec 2019 | $39M | $1M | $38M | $-0.35 | — |
| Dec 2018 | $-38M | $1M | $-39M | $0.06 | — |
SEC filings
- Nov 18, 20266-KReport of foreign issuer
- Nov 12, 20266-KReport of foreign issuer
- Nov 5, 20266-KReport of foreign issuer
- Oct 27, 20266-KReport of foreign issuer
- Oct 21, 20266-KReport of foreign issuer
- Oct 20, 20266-KReport of foreign issuer
- Sep 17, 20266-KReport of foreign issuer
- Sep 17, 20266-KReport of foreign issuer
- Sep 17, 20266-KReport of foreign issuer
- Sep 10, 20266-KReport of foreign issuer
- Sep 2, 20266-KReport of foreign issuer
- Aug 19, 20266-KReport of foreign issuer
Official filings of Innate Pharma SA with the US Securities and Exchange Commission.
Annual results
- Revenue
- $10 M
- Operating income
- $-61 M
- Net income
- $-55 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $74 M
- Total liabilities
- $99 M
- Total equity
- $-26 M
As of December-2025
Markets and events: Innate Pharma SA#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 1,376 shares at $1.48
- : 317 shares at $1.58
- : 945 shares at $1.46
- : 45 shares at $1.48
- : 278 shares at $1.43
Innate Pharma SA scorecard#
Passes 1 of the 11 checks that could be worked out: strongest in growth (1 of 6), weakest in profitability (0 of 4). Fiscal year 2025.
Valuationnot known
Growth1 of 6
Profitability0 of 4
Financial health0 of 1
Shareholder returnsnot known
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Innate Pharma SA's statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -599.5% | -60.5% | |
| Net margin | -545.9% | -70.4% | |
| Revenue growth, 3 years a year | -44.9% | 12.9% | |
| Revenue growth | -53.3% | 16.0% | |
| Free cash flow margin | -587.2% | -61.7% |
0of 6on the Piotroski tests of financial strength
- Revenue fell 53.3% against the year before.
- Net loss of $55 million, the 7th loss-making year in a row.
- Free cash flow was negative: -$60 million.
- Shareholders' equity is negative: -$26 million.
Innate Pharma SA: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in EUR millions; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 9.0 | 20 | 62 | 58 | 25 | 70r | 85r | 94 | 44 | |
| Research and development | 44 | 52 | 56 | 52 | 47 | 50r | 63r | 70 | 67 | |
| Selling, general and administrative | — | 20 | 18 | 22 | 26 | 19r | 21r | 18 | 17 | |
| Selling and marketing | 0.5 | 0.4 | 0.4 | 0.7 | 0.5 | 0.5r | 0.6r | 0.5 | 0.6 | |
| Total costs and expenses | 63 | 72 | 74 | 115 | 73 | 69r | 84r | 88 | 84 | |
| Operating income | −54 | −52 | −13 | −57 | −48 | 1.1r | 1.6r | 5.1 | −40 | |
| Interest and finance income | 8.0 | 6.1 | 6.9 | 4.8 | 6.3 | 4.9 | 11 | 6.0 | 2.5 | |
| Interest expense and finance costs | 3.1 | 4.0 | 1.8 | 5.3 | 4.0 | 6.8 | 5.0 | 8.4 | 11 | |
| Income before tax | −49 | −49 | −7.6 | −58 | −45 | −0.8r | 7.9r | 2.7 | −48 | |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0.3 | 0.4 | |
| Income from continuing operations | −49 | −49 | −7.6 | −58 | −45 | −0.8 | 7.9 | — | — | |
| Income from discontinued operations | — | 0 | 0 | −0.1 | −7.3 | −63 | −29 | — | — | |
| Net income including minority interests | −49 | −49 | −7.6 | −58 | −53 | −64 | −21 | 3.0 | −48 | |
| Earnings per share, basic | -0.55 | -0.61 | -0.09 | -0.73 | -0.66 | -0.81 | -0.31 | 0.05 | -0.89 | |
| Earnings per share, diluted | -0.55 | -0.61 | -0.09 | -0.73 | -0.66 | -0.81 | -0.31 | 0.05 | -0.89 | |
| Shares, weighted average (basic) | 90 | 81 | 80 | 80 | 80 | 79 | 67 | 59 | 54 | |
| Shares, weighted average (diluted) | — | 81 | 80 | 80 | 80 | 79 | 67 | — | — | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 28 | 66 | 71 | 84 | 104 | 137 | 203 | 152 | 99 | |
| Short-term investments | 6.2 | 14 | 22 | 17 | 16 | 15 | 16 | 15 | 17 | |
| Receivables | 12 | 5.0 | 56 | 38 | 18 | 22 | 19 | 152 | 21 | |
| Current assets | 47 | 86 | 148r | 140 | 138 | 173 | 238 | 320 | 138 | |
| Property, plant and equipment | — | — | — | 8.5 | 10 | 12 | 12 | 11r | 11 | |
| Other intangible assets | 0 | 0 | 0.4 | 1.6r | 44 | 46 | 97 | 85 | 46 | |
| Non-current assets | 16 | 25 | 27r | 59r | 129 | 134 | 164 | 132 | 118 | |
| Total assets | 63 | 111 | 175r | 199r | 267 | 307 | 401 | 451 | 255 | |
| Accounts payable | 15 | 16 | 17 | 21 | 29 | 30 | 50 | 92 | 25 | |
| Current liabilities | 37 | 33 | 40r | 41 | 80 | 45 | 122 | 197 | 74 | |
| Non-current liabilities | 48 | 69 | 84r | 104r | 80r | 106 | 62 | 87 | 95 | |
| Retained earnings | — | — | — | — | — | — | −135 | −139 | −104 | |
| Total equity | −22 | 8.8 | 52 | 54 | 107 | 156 | 217 | 167r | 99r | |
| Total liabilities and equity | 63 | 111 | 175r | 199r | 267 | 307 | 401 | 451 | 255 | |
| Shares outstanding | — | — | — | 80 | — | — | — | — | — | |
| Cash-flow statement | ||||||||||
| Depreciation and amortization | 1.4 | 2.0 | 5.1 | 45 | 4.6 | 57 | 17 | 7.4 | 4.4 | |
| Share-based compensation | 2.6 | 3.9 | 4.3 | 4.2 | 2.6 | 2.5 | 3.8 | 2.7 | 9.8 | |
| Cash from operating activities | −53 | −6.9 | −33r | −19r | −58 | −52 | 35 | −33 | −48 | |
| Capital expenditure | −0.1 | −0.4 | −0.4 | −0.5 | −0.9 | −0.9 | −1.3 | −0.9 | −3.0 | |
| Intangible assets bought | 0 | 0 | −2.0 | −0.6 | −0.4 | −10 | −64 | −0.6 | −3.1 | |
| Cash from investing activities | 7.3 | 9.2 | 21r | 1.9 | −0.9 | −13 | −62 | 24 | −29 | |
| Debt issued | 0 | 0 | 0 | 0 | 29 | 1.4 | 14 | 0 | 1.7 | |
| Debt repaid | −8.9 | −8.9 | −2.4 | −2.0 | −2.1 | −2.2 | −2.0 | −1.3r | −1.2 | |
| Shares issued | 15 | 2.9 | 0.4 | 0.2 | 0.5 | 0.0 | 0.0 | 0.1 | — | |
| Cash from financing activities | 6.1 | −6.0 | −2.0 | −1.8 | 27r | −1.2 | 78 | 61 | 0.9 | |
| Exchange-rate effect on cash | 1.1 | −0.5 | 0.3 | −0.4 | −0.5 | 0.2 | 0.0 | −0.0 | 0.1 | |
| Change in cash | −38 | −4.2 | −14 | −20r | −33r | −66 | 51r | 53 | −77 | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Dec 31, 2025
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2013 | $27 M | No. 1 | $10 to $50 million | 6 | equity | SEC |
How Innate Pharma SA compares in Biotechnology
- Revenue$10 M · higher than 44% of 649
- Net margin-545.9% · higher than 12% of 407
- Revenue growth-53.3% · higher than 16% of 441
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Innate Pharma SA🇫🇷 | $230 M | — | -545.9% | -53.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
How current the figures are
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2024
- Profile updated:
- Nov 22, 2026
How each figure is collected: methodology. Market caps in US dollars unless you switch the currency.
Work at Innate Pharma SA? Verify and update this profile — free
Show Innate Pharma SA's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.